Linezolid + Ethambutol
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Tuberculosis Without Resistance to Rifampicin
Conditions
Pulmonary Tuberculosis Without Resistance to Rifampicin
Trial Timeline
Jan 1, 2014 → Jun 1, 2016
NCT ID
NCT01994460About Linezolid + Ethambutol
Linezolid + Ethambutol is a phase 2 stage product being developed by Pfizer for Pulmonary Tuberculosis Without Resistance to Rifampicin. The current trial status is unknown. This product is registered under clinical trial identifier NCT01994460. Target conditions include Pulmonary Tuberculosis Without Resistance to Rifampicin.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Tuberculosis Without Resistance to Rifampicin were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01994460 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Pulmonary Tuberculosis Without Resistance to Rifampicin